BALAXI PHARMACEUTICALS share price
NSE: BALAXIPharmaceuticals & BiotechnologySmall Cap
Formerly Balaxi Ventures
Last close ₹20.91down ₹0.09 (0.43%)
Share price at the NSE close on 23 Oct 2026. Previous close ₹21.00.
52-week range of traded prices to 23 Oct 2026
₹15.20Low, 27 Mar 2026₹43.85High, 4 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹115 Cr2,722nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 5 Aug 2026
- 47.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 Jun 2026
- 0.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 5 Aug 2026
- 1.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 5 Aug 2026
- 2.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 Jun 2026
- 0.22
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 40,13985.6% delivered
Results
Standalone, as consolidated accounts are on record for only 7 of the last ten years; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 5 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹16 Crdown 23.00%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹1.25 CrQuarter to Mar 2026: ₹0.16 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- −8.0%
Revenue by year
Peak revenue ₹108 Cr, year to Mar 2023
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 1 of the 9 years shown
| ₹ crore | Sep 2024Filed 5 Nov | Dec 2024Filed 10 Feb | Mar 2025Filed 30 May | Jun 2025Filed 5 Aug | Sep 2025Filed 11 Nov | Dec 2025Filed 28 Jan | Mar 2026Filed 30 Jun | Jun 2026Filed 5 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 21.2 | 11.2 | 9.6 | 16.7 | 19.3 | 24.6 | 20.2 | 15.6 |
| Net profit | 1.7 | 1.7 | −1.2 | 0.2 | 3.3 | 1.5 | 0.2 | −1.3 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 7.9% | 15.6% | −12.2% | 1.2% | 16.9% | 6.2% | 0.8% | −8.0% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, SPECIALIZED WHOLESALE, which carries all its revenue.
Valuation
Today, against the company's own history.PE ratio and valuation history
Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
At or below today's level on 90% of 992 trading days over the last 5 years.
LowestHighest
Its median11.7Industry median28.1
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 2% of 924 trading days since Nov 2022.
LowestHighest
Its median2.0Industry median2.9
EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.17.3
At or below today's level on 89% of 924 trading days since Nov 2022.
LowestHighest
Its median9.1Industry median18.7
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 87% of 1,947 trading days since Feb 2017.
LowestHighest
Its median0.00%Industry median0.53%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −75.5% | +43.1% | −82.9% | 0.0% |
| 3 years | −47.1% | −34.0% | −19.9% | 0.0% |
| 5 years | −31.6% | −21.0% | −13.4% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to BALAXI PHARMACEUTICALS in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Speciality MedicinesSPML | 125 | 9.6 | 1.7 | – | – | – | 18.3% | – | 0.00% |
 Godavari DrugsGODAVARI | 122 | 29.3 | 1.6 | 18.5 | +4.8% | +9.7% | 7.0% | 4.9% | 0.00% |
| Himalaya Nutravedics IndiaHNIL | 121 | – | – | – | – | – | – | – | 0.00% |
 Parnax LabPARNAXLAB | 119 | 13.3 | 1.2 | 7.9 | +31.9% | −17.3% | 10.0% | 9.3% | 0.00% |
 Krebs Biochemicals and IndustriesKREBSBIO | 112 | – | – | – | −29.7% | – | – | −14.4% | 0.00% |
 Makers LaboratoriesMAKERSL | 110 | 32.3 | 1.5 | 6.1 | +17.6% | −61.6% | 4.8% | 11.1% | 0.00% |
 Tyche IndustriesTYCHE | 107 | 24.0 | 0.8 | – | −21.0% | −63.5% | 3.2% | −2.5% | 3.36% |
 Alpa LaboratoriesALPA | 104 | – | 0.6 | – | +0.5% | – | – | −1.8% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.Highest ₹0.10 a share, year to Mar 2022.
| Ex-date | Type | Per share |
|---|---|---|
| 1 Jul 2022 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.50 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
Aug 2026
24 Aug · Management
BALAXI PHARMACEUTICALS share price by year
Each calendar year to 2025.BALAXI PHARMACEUTICALS share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 26.87 | −62.8% | 81.86 | 26.77 |
| 2024 | 72.31 | −16.4% | 142.01 | 70.12 |
| 2023 | 86.47 | −28.8% | 127.72 | 80.46 |
| 2022 | 121.44 | +18.3% | 138.35 | 67.50 |
| 2021 | 102.62 | −21.0% | 143.28 | 93.01 |
| 2020 | 129.98 | +700.4% | 208.03 | 13.54 |
| 2019 | 16.24 | +184.9% | 26.75 | 5.70 |
| 2018 | 5.70 | +91.9% | 6.02 | 2.83 |
| 2017 | 2.97 | −22.7% | 7.20 | 2.58 |
| 2016 | 3.84 | −25.1% | 5.80 | 2.36 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. The close is the year's last trade for 2018 (15 Oct 2018), 2017 (19 Dec 2017) and 2016 (8 Dec 2016).
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 21.18 | 21.18 | 19.35 | 20.91 | 20.39 | 40,139 | 85.6% |
| 22 Oct 2026 | 21.10 | 21.30 | 19.16 | 21.00 | 20.33 | 62,006 | 65.4% |
| 21 Oct 2026 | 22.35 | 22.35 | 21.00 | 21.10 | 21.35 | 23,032 | 82.9% |
| 19 Oct 2026 | 22.09 | 22.34 | 21.60 | 21.76 | 22.01 | 19,900 | 74.8% |
| 16 Oct 2026 | 22.60 | 22.60 | 21.80 | 22.09 | 22.15 | 13,444 | 94.5% |
| 15 Oct 2026 | 22.40 | 22.62 | 21.85 | 22.13 | 22.20 | 10,714 | 76.1% |
| 14 Oct 2026 | 22.40 | 22.40 | 21.70 | 22.18 | 22.23 | 8,605 | 80.2% |
| 13 Oct 2026 | 22.58 | 22.58 | 21.50 | 22.19 | 21.94 | 26,229 | 74.3% |
| 12 Oct 2026 | 22.33 | 22.90 | 22.30 | 22.36 | 22.52 | 16,602 | 72.9% |
| 9 Oct 2026 | 22.40 | 22.79 | 22.09 | 22.33 | 22.41 | 13,772 | 79.6% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 30 May 2024 | Split | 0.2000 | Each share became 5. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- Legal name
- BALAXI PHARMACEUTICALS LIMITED
- NSE symbol
- BALAXI
- ISIN
- INE618N01022
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Nov 2015
- Face value
- ₹2
- Former symbols
- ANANDAMRUB